Using cells devoid of RAS proteins as tools for drug discovery

@article{Urosevic2009UsingCD,
  title={Using cells devoid of RAS proteins as tools for drug discovery},
  author={J. Urosevic and E. Sum and V. Moneo and M. Drosten and Alma Dhawahir and M. Becerra and A. Carnero and M. Barbacid},
  journal={Molecular Carcinogenesis},
  year={2009},
  volume={48}
}
Mutational activation of RAS proteins occurs in nearly 30% of all human tumors. To date direct pharmacological inhibition of RAS oncoproteins has not been possible. As a consequence, current strategies are focusing on the development of inhibitors that target those kinases acting downstream of RAS proteins, including those of the RAF/MEK/ERK and PI3K/AKT pathways. Most of these inhibitors have undesired off‐target effects that mask the potential therapeutic effect of blocking their targeted… Expand
Multivalent Small-Molecule Pan-RAS Inhibitors
Ras activation of Erk restores impaired tonic BCR signaling and rescues immature B cell differentiation
Multivalent Small-Molecule Pan-RAS Inhibitors Graphical

References

SHOWING 1-10 OF 51 REFERENCES
BRAF mutation predicts sensitivity to MEK inhibition
Raf kinases: Oncogenesis and drug discovery
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase*
RAS signalling is abnormal in a c-raf1 MEK1 double mutant.
...
1
2
3
4
5
...